HC-03

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameHC-03
Drug Alias NameHC-03
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitorsIsocitrate dehydrogenase [NADP], mitochondrial inhibitors
TargetsIsocitrate dehydrogenase [NADP], mitochondrialIsocitrate dehydrogenase [NADP] cytoplasmic
Therapy Area/IndicationsBile Duct NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTaizhou Highsun Pharmaceutical Co LtdNerviano Medical Sciences Srl
China Registration ClassN/A

Develop Information

Active CompaniesNerviano Medical Sciences SrlTaizhou Highsun Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsBile Duct NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A